- Presentations
- 3
- Markets
- 1
Zejula is a brand of Niraparib marketed by GlaxoSmithKline, with 3 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Niraparib
- Brand owner
- GlaxoSmithKline
- Registered in
- United States
- Strengths and forms
- 100 mg tablet, 200 mg tablet, 300 mg tablet
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Zejula 100 mg tabletOral | GlaxoSmithKline | US FDA | Available on request |
| Zejula 200 mg tabletOral | GlaxoSmithKline | US FDA | Available on request |
| Zejula 300 mg tabletOral | GlaxoSmithKline | US FDA | Available on request |
Brand names and trademarks belong to their owners and are used only to identify products.
Request Zejula
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.